Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Knowing when to use financial planning services can significantly impact your financial health. Discover the right timing for assistance.
24,264 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Goldman Sachs-backed GPIQ is carving out a niche as a high-yield Nasdaq-100 income vehicle. The fund uses a laddered ...
Bitcoin holds above $74,000 as policymakers prepare to announce rate decisions this week, setting the tone for crypto...
Hess Midstream’s capital return program is under review as a $60 million buyback coincides with a high payout ratio a...
Credit conditions are tightening ahead of any Fed move, driven by higher bond yields and a wave of AI financing. Inve...
A new policy debate threatens to tax the income universities earn from licensing taxpayer-funded research, potentiall...
As the 10-year yield hovers near 4.4%, many investors chase top-yield REITs for income. The real cost chasing reit be...
DraftKings reports a mixed Q1 2026 while signaling growth hinges on prediction markets and regulatory clarity. A path...
A new analysis reveals that private equity inside 401(K) plans can charge 2%-3% annually, creating a long-term drag t...
Citi initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
A New York rally billed as a discussion on the economy devolved into tangents about toiletries and voter rules, under...
Small-cap stocks have shown strength this year, but Wells Fargo argues the rally masks deteriorating earnings trends ...